Procore is a biotechnology company singly focused on developing solutions that improve the quality of lives of patients suffering from joint and bone diseases. The company’s flagship RegenoGel family is based on proprietary HAProLink technology, a platform technology that links hyaluronic acid to a protein of choice to create a microenvironment for the body to heal itself via natural, gentle cartilage and bone regeneration.
RegenoGel products are approved by Israel’s Ministry of Health and have been commercially available since 2016. RegenoGel and the company’s platform technologies are based on the seminal work in biomimetic innovation of Prof. Avner Yayon’s, Procore’s founder.
With a vision to emerge as a new gold standard and recognized for its far-reaching potential the company participates in EU-funded research consortia and projects as part of the EU 7th framework programs and the Horizon 2020 Marie Sklodowska-Curie (MSCA) program for cartilage repair and regeneration.
Procore operates a cGMP-, ISO 9001:2008- and ISO13485:2016-accredited cell therapy facility and has extensive experience producing clinical grade products.
Procore was established in 2008 and has headquarters, production facilities and R&D laboratories in the Weizmann Science Park in central Israel.